Savara Inc — Investor Relations & Filings

Savara Inc. is a clinical-stage biopharmaceutical company that develops therapies for rare respiratory diseases. The company's lead product candidate is molgramostim nebulizer solution, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). This candidate, which has the conditionally accepted trade name MOLBREEVI, is in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease. Savara has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for MOLBREEVI for this indication.